title: Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
abstract: Despite recent advances made in its treatment, multiple myeloma (MM) remains an incurable B cell malignancy. Thus, the objective for treating these patients is to prolong overall survival (OS) and preserve patients' quality of life. We have analyzed data from 264 consecutive MM patients who had their initial visit between July 1, 2004 and December 1, 2014 and have received treatment in a single clinic specializing in MM. We determined their progression-free survival (PFS, OS, and 5-year OS). The PFS for frontline (n = 165 treatments), salvage (n = 980), and all treatments (n = 1145) were 13.9, 4.6, and 5.5 months, respectively. The median OS of all patients was 98 months with a 5-year survival of 74%. The results of this study show a marked improvement in OS for unselected MM patients compared with historical data. There were no significant differences in OS between patients with different International Staging System (ISS) stages. Younger patients (<65 years old) showed a longer OS. The results of this study should help physicians predict outcomes for MM patients and be encouraging for patients with this B cell malignancy.
authors.affiliation: Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA.
authors.forename: Ariana
authors.initials: A
authors.lastname: Berenson
authors.affiliation: Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA.
authors.forename: Suzie
authors.initials: S
authors.lastname: Vardanyan
authors.affiliation: Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: David
authors.affiliation: Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA.|James R. Berenson, MD, Inc., Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd, Suite 310, West Hollywood, CA, USA.
authors.forename: James
authors.initials: J
authors.lastname: Wang
authors.affiliation: Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA.
authors.forename: Nika Manik
authors.initials: NM
authors.lastname: Harutyunyan
authors.affiliation: Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA.
authors.forename: Jillian
authors.initials: J
authors.lastname: Gottlieb
authors.affiliation: Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA.
authors.forename: Ran
authors.initials: R
authors.lastname: Halleluyan
authors.affiliation: Oncotherapeutics, 9201 W. Sunset Blvd, Suite 317, West Hollywood, CA, USA.
authors.forename: Tanya M
authors.initials: TM
authors.lastname: Spektor
authors.affiliation: Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA.|James R. Berenson, MD, Inc., Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd, Suite 310, West Hollywood, CA, USA.
authors.forename: Kyle A
authors.initials: KA
authors.lastname: Udd
authors.affiliation: Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA.
authors.forename: Shahrooz
authors.initials: S
authors.lastname: Eshaghian
authors.affiliation: James R. Berenson, MD, Inc., Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd, Suite 310, West Hollywood, CA, USA.
authors.forename: Youram
authors.initials: Y
authors.lastname: Nassir
authors.affiliation: James R. Berenson, MD, Inc., Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd, Suite 310, West Hollywood, CA, USA.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Eades
authors.affiliation: James R. Berenson, MD, Inc., Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd, Suite 310, West Hollywood, CA, USA.
authors.forename: Regina
authors.initials: R
authors.lastname: Swift
authors.affiliation: Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA. jberenson@imbcr.org.|James R. Berenson, MD, Inc., Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd, Suite 310, West Hollywood, CA, USA. jberenson@imbcr.org.|Oncotherapeutics, 9201 W. Sunset Blvd, Suite 317, West Hollywood, CA, USA. jberenson@imbcr.org.
authors.forename: James R
authors.initials: JR
authors.lastname: Berenson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000069286:Bortezomib / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D009842:Oligopeptides / Q000008:administration & dosage; D010044:Outpatient Clinics, Hospital / Q000639:trends*; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D009842:Oligopeptides; D013792:Thalidomide; D000069286:Bortezomib; C524865:carfilzomib; D000077269:Lenalidomide
keywords: Multiple myeloma; Overall survival; Progression-free survival